Published in Medical Letter on the CDC and FDA, October 8th, 2006
Arformoterol tartrate inhalation solution is a long-acting beta-agonist formulation proposed for long-term maintenance treatment of chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. A New Drug Application (NDA) for arformoterol tartrate inhalation solution is currently under U.S. Food and Drug Administration (FDA) review. The Prescription Drug User Fee Act (PDUFA) date for arformoterol is October 12, 2006. A PDUFA date...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA